文献速递耳科与耳神经头颈外科

2型神经纤维瘤病患者人工耳蜗的纵向性能表现

Longitudinal Performance of Cochlear Implants in Neurofibromatosis Type 2.
PubMed 文献 · Laryngoscope · 2023-09-12

该研究回顾性分析了2001至2022年间单中心12例2型神经纤维瘤病(NF2)患者共14例人工耳蜗的纵向使用结局,发现35.7%的耳蜗出现弃用或取出,平均取出间隔9.4年(范围3-14年),最大肿瘤直径是唯一影响耳蜗使用结局的变量(p=0.028),患者平均获益13.85年耳蜗使用时间,最大纯音平均改善45.0±29.0 dB。

要点

  • 14例人工耳蜗中35.7%出现弃用或取出,平均取出间隔9.4年(范围3-14年)
  • 最大肿瘤直径是唯一影响耳蜗使用结局的变量(p=0.028)
  • 患者平均获益13.85年耳蜗使用时间,最大纯音平均改善45.0±29.0 dB

核心结论

  • 尽管NF2具有复发特性,患者仍可从人工耳蜗获得听力学获益
  • 较大的肿瘤尺寸可能与纵向耳蜗失败相关

研究设计与样本

  • 单学术机构回顾性综述,纳入2001至2022年因NF2听力损失后接受人工耳蜗的患者
  • 共12例患者和14例人工耳蜗
  • 主要结局为人工耳蜗弃用或取出
  • 分析包括术后500、1000、2000 Hz纯音平均(PTA)、肿瘤大小、既往手术和共病抑郁

主要发现

  • 35.7%的人工耳蜗(14例中5例)导致弃用或取出
  • 平均取出间隔为9.4年(范围3-14年)
  • 取出组中20%有既往手术、80%有共病抑郁诊断,完整组分别为22.2%和22.2%
  • 最大肿瘤直径是唯一影响人工耳蜗使用结局的变量(p=0.028)
  • 长期数据显示患者平均获益13.85年人工耳蜗使用时间,最大PTA改善45.0±29.0 dB

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Cochlear implants (CIs) are a well-established treatment modality for hearing loss due to neurofibromatosis type 2 (NF2). Our aim is to investigate variables that affect longitudinal performance of CIs among patients with NF2. STUDY DESIGN: Retrospective review at a single academic institution consisting of patients who have received cochlear implants following hearing loss due to NF2. METHODS: The primary outcome examined was CI disuse or explantation. Associated clinical and surgical variables were analyzed using descriptive statistics. These included postoperative pure tone average (PTA) at 500, 1000, and 2000 Hz, tumor size, previous surgery, and comorbid depression. RESULTS: A total of 12 patients and 14 cochlear implants received at our institution from 2001 to 2022 were included. Notably, 35.7% of CIs (5 out of 14 cases) resulted in disuse or explantation. The average interval until explant was 9.4 years (range 3-14 years). In explanted CI cases, 20% had previous surgery and 80% had a diagnosis of comorbid depression as compared to 22.2% and 22.2%, respectively, in intact CI cases. Maximum tumor diameter was the only variable found to impact CI usage outcome (p = 0.028). Long-term data showed that on average, patients benefit from 13.85 years of CI utility and a maximum PTA improvement of 45.0 ± 29.0 dB. CONCLUSION: Despite the recurrent nature of NF2, patients continue to receive audiological benefit from cochlear implants. We found that larger tumor size may be associated with longitudinal CI failure. LEVEL OF EVIDENCE: 4 Laryngoscope, 134:1847-1853, 2024.

来源:Laryngoscope,查看原文。版权归原作者所有。

引用

  1. Seo S, Shen S, Ding AS, et al. Longitudinal Performance of Cochlear Implants in Neurofibromatosis Type 2. Laryngoscope. 2023. PMID: 37698390. doi:10.1002/lary.31044

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。